Antibacterial Therapy and Newer Agents , An Issue of Medical Clinics of North America, 1st Edition
Author :
By Keith S. Kaye, MD, MPH and Donald Kaye, MD, MACP
This issue of Medical Clinics of North America brings the physician up to date on the newest agents for antibacterial therapy. New drugs are covered, as well as new approaches. Topics include the newer fluoroquinolones; epidemiology, mole
...view more
This issue of Medical Clinics of North America brings the physician up to date on the newest agents for antibacterial therapy. New drugs are covered, as well as new approaches. Topics include the newer fluoroquinolones; epidemiology, molecular mechanisms, and clinical management of pathogens resistant to antibacterial agents; current use for old antibacterial agents, including polymyxins, rifamycins, and aminoglycosides; topical antibacterial agents; newer beta-lactam antibiotics, including doripenem, ceftobiprole. ceftaroline, and cefepim; the use of antibacterial agents in renal failure; antibiotics for gram positive bacterial infections, including vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinolones, daptomycin, telavancin, and ceftaroline; as well as macrolides, ketolides, and glycylcyclines, including azithromycin, clarithromycin, telithromycin, and tigecycline.
This issue of Medical Clinics of North America brings the physician up to date on the newest agents for antibacterial therapy. New drugs are covered, as well as new approaches. Topics include the newer fluoroquinolones; epidemiology, molecular mechanisms, and clinical management of pathogens resistant to antibacterial agents; current use for old antibacterial agents, including polymyxins, rifamycins, and aminoglycosides; topical antibacterial agents; newer beta-lactam antibiotics, including doripenem, ceftobiprole. ceftaroline, and cefepim; the use of antibacterial agents in renal failure; antibiotics for gram positive bacterial infections, including vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinolones, daptomycin, telavancin, and ceftaroline; as well as macrolides, ketolides, and glycylcyclines, including azithromycin, clarithromycin, telithromycin, and tigecycline.
Author Information
By Keith S. Kaye, MD, MPH, Professor of Internal Medicine and Infectious Diseases
Wayne State University School of Medicine
Corporate Director of Infection Prevention
Hospital Epidemiology and Antimicrobial Stewardship
Detroit Medical Center
Detroit, MI and Donald Kaye, MD, MACP
By Keith S. Kaye, MD, MPH, Professor of Internal Medicine and Infectious Diseases
Wayne State University School of Medicine
Corporate Director of Infection Prevention
Hospital Epidemiology and Antimicrobial Stewardship
Detroit Medical Center
Detroit, MI and Donald Kaye, MD, MACP
https://www.asia.elsevierhealth.com/antibacterial-therapy-and-newer-agents-an-issue-of-medical-clinics-of-north-america-9781455722914.html299971Antibacterial Therapy and Newer Agents , An Issue of Medical Clinics of North Americahttps://www.asia.elsevierhealth.com/media/catalog/product/9/7/9781455722914_7.jpg74.6982.99USDInStock/Clinics/Medicine & Surgery/Clinical/General Medicine/Medicine/Clinical/General Medicine/Clinics/Clinics/Medicine/Clinical/General Medicine/Japan Titles438872543351025054591505466652550415259874526316014182692433508848865365054553514512052598335259873This issue of Medical Clinics of North America brings the physician up to date on the newest agents for antibacterial therapy. New drugs are covered, as well as new approaches. Topics include the newer fluoroquinolones; epidemiology, molecular mechanisms, and clinical management of pathogens resistant to antibacterial agents; current use for old antibacterial agents, including polymyxins, rifamycins, and aminoglycosides; topical antibacterial agents; newer beta-lactam antibiotics, including doripenem, ceftobiprole. ceftaroline, and cefepim; the use of antibacterial agents in renal failure; antibiotics for gram positive bacterial infections, including vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinolones, daptomycin, telavancin, and ceftaroline; as well as macrolides, ketolides, and glycylcyclines, including azithromycin, clarithromycin, telithromycin, and tigecycline. This issue of Medical Clinics of North America brings the physician up to date on the newest agents for antibacterial therapy. New drugs are covered, as well as new approaches. Topics include the newer fluoroquinolones; epidemiology, molecular mechanisms, and clinical management of pathogens resistant to antibacterial agents; current use for old antibacterial agents, including polymyxins, rifamycins, and aminoglycosides; topical antibacterial agents; newer beta-lactam antibiotics, including doripenem, ceftobiprole. ceftaroline, and cefepim; the use of antibacterial agents in renal failure; antibiotics for gram positive bacterial infections, including vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinolones, daptomycin, telavancin, and ceftaroline; as well as macrolides, ketolides, and glycylcyclines, including azithromycin, clarithromycin, telithromycin, and tigecycline.00add-to-cart97814557229142011 and earlierProfessionalBy Keith S. Kaye, MD, MPH and Donald Kaye, MD, MACP20111Book152w x 229h (6.00" x 9.00")Saunders224Jul 8, 2011IN STOCKBy <STRONG>Keith S. Kaye</STRONG>, MD, MPH, Professor of Internal Medicine and Infectious Diseases
Wayne State University School of Medicine
Corporate Director of Infection Prevention
Hospital Epidemiology and Antimicrobial Stewardship
Detroit Medical Center
Detroit, MI and <STRONG>Donald Kaye</STRONG>, MD, MACPClinicsClinicsThe Clinics: Internal MedicineUnited StatesNoNoNoNoPlease SelectPlease SelectPlease Select